Antibody Modulating The Differentiation And Function Of Dendritic Cells Via Binding Intercellular Adhesion Molecule-1 And Use Thereof

Abstract

The present invention relates to an antibody binding to human intercellular adhesion molecule-1 (ICAM-1) where the antibody is able to modulate the differentiation status of dendritic cells and prolong the graft survival. In addition, the present invention provides a pharmaceutical composition comprising the antibody, and method of using them for the treatment of disease.

1 . An antibody that competes with an antibody produced by a hybridoma deposited as an accession number of KCLRF-BP-00198 for binding to domain 1 of human intercellular adhesion molecules-1 (ICAM-1). 
     
     
         2 . An antibody that binds to domain 1 of human ICAM-1 without inhibiting the binding of human ICAM-1 to human leukocyte function antigen-1 (LFA-1). 
     
     
         3 . The antibody according to  claim 1 , wherein the antibody is in isolated form. 
     
     
         4 . The antibody according to  claim 1 , wherein the antibody is chimeric antibody or humanized antibody. 
     
     
         5 . The antibody according to  claim 1 , wherein the antibody is a monoclonal antibody. 
     
     
         6 . The antibody according to  claim 1 , wherein the antibody modulates the differentiation of dendritic cells via binding ICAM-1. 
     
     
         7 . A pharmaceutical composition comprising the antibody of  claim 1 . 
     
     
         8 . The pharmaceutical composition according to  claim 7 , wherein the antibody is in isolated form. 
     
     
         9 . The pharmaceutical composition according to  claim 7 , wherein the antibody is chimeric antibody or humanized antibody. 
     
     
         10 . The pharmaceutical composition according to  claim 7 , wherein the antibody is a monoclonal antibody. 
     
     
         11 . A pharmaceutical composition for modulating the differentiation of dendritic cells via binding ICAM-1, comprising the antibody of  claim 1 . 
     
     
         12 . A pharmaceutical composition for suppressing rejection of transplanted cells or organs, or suppressing graft versus host disease by transplanted hematotoietic cells, comprising the antibody of  claim 1 .